Research-based pharmaceutical firm RPG Life Sciences reported a 16.5% year-on-year increase in revenue from operations to ₹211.6 crore in the second quarter of FY27.
The company reported a profit of ₹28.22 crore in Q2 FY27, down from ₹30.58 crore in Q1 FY27 and ₹36.85 crore in Q2 FY26. The year-on-year decline was partly influenced by an exceptional gain of ₹11.22 crore included in the year-ago quarter.
Adjusted EBITDA, excluding one-off costs related to the API acquisitions and restructuring, rose 15% to ₹50.1 crore, company said in a press release.
Gross margin expanded by 260 basis points during the quarter despite external cost pressures. Adjusted EBITDA margin stood at 23.7%, compared with 24% in the year-ago period. Reported EBITDA, including the one-off costs of ₹5.5 crore, stood at ₹44.7 crore, while adjusted profit before tax grew 11.3%.
The acquired API manufacturing sites contributed ₹0.5 crore to revenue in Q2, with full revenue contribution from both sites expected to begin in Q3 FY27 following the completion of the transactions in September.
Domestic formulations grows 11.6%
The company informed that domestic formulations business grew 11.6% in FY27, supported by volume growth, specialty therapies and new launches. RPG Life Sciences said it became the fourth-fastest-growing company in the Indian Pharmaceutical Market (IPM) and entered the top 50 in the market ranking.
Its flagship brand, Naprosyn, crossed ₹100 crore in sales.
The international formulations business grew 6.4% in Q2 and 7% in the first half of FY27, supported by performance across key products and markets.
The company said that it is pursuing growth through new market registrations, contract development and manufacturing opportunities, business development and cost initiatives.
API business expands through acquisitions
The API business recorded sales of ₹27.5 crore in Q2 and ₹54.1 crore in the first half of FY27. During the quarter, RPG Life Sciences transferred its API business to RPG Active Pharma, brought in InvAscent as a strategic investor and completed the acquisitions of two API plants — Actis Generics and Raghava Lifesciences.
Managing Director Ashok Nair said the company would focus on integrating the acquired facilities, improving asset utilisation, expanding international business, strengthening customer engagement and reducing costs.
He added that the company would continue to focus on domestic formulations, improve the competitiveness of its international formulations business and scale up the expanded API operations.
Shares of RPG Life Sciences rose 5.52% to ₹3,001 on October 29, ahead of the company’s Q2 FY27 earnings announcement.